- /
- Supported exchanges
- / US
- / BLTE.NASDAQ
Belite Bio Inc ADR (BLTE NASDAQ) stock market data APIs
Belite Bio Inc ADR Financial Data Overview
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Belite Bio Inc ADR (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Belite Bio Inc ADR data using free add-ons & libraries
Get Belite Bio Inc ADR Fundamental Data
Belite Bio Inc ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -67 398 248
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-18
- EPS/Forecast: -0.4975
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Belite Bio Inc ADR News
New
Belite Bio outlines regulatory path and $275.6M cash position while preparing for Tinlarebant commercialization
Earnings Call Insights: Belite Bio (BLTE) Q3 2025 MANAGEMENT VIEW * CEO Yu-Hsin Lin highlighted the completion of Phase III PHOENIX trial enrollment with 530 subjects for geographic atrophy and th...
Belite Bio GAAP EPS of -$0.28 beats by $0.20
* Belite Bio press release [https://seekingalpha.com/pr/20300408-belite-bio-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update] (BLTE [https://seekingalpha.com/symbol/BLTE]...
After-Hours Earnings Report for November 10, 2025 : OXY, RKLB, ASTS, RGTI, SARO, WULF, BLTE, PLUG, MLYS, TDW, BBAI, JAMF
The following companies are expected to report earnings after hours on 11/10/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Occidental Petroleum Corporation (OXY)...
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Belite Bio, Inc Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) Completed $15 million registered direct offering and $125 million private placem...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.